CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
 

Stemline Therapeutics Inc's Working Capital Ratio

STML's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth




STML Working Capital Ratio (Mar 31 2018)
I. Quarter
(Dec 31 2017)
IV. Quarter
(Sep 30 2017)
III. Quarter
(Jun 30 2017)
II. Quarter
(Mar 31 2017)
I. Quarter
Y / Y Current Liabilities Change 48.32 % 93.48 % 58.69 % 55.44 % 54.92 %
Y / Y Current Assets Change 11.57 % 10.64 % 29.59 % 9.65 % 78.18 %
Working Capital Ratio MRQ 5.14 2.63 4.57 4.65 6.83
Overall Ranking # # # # #
Seq. Current Liabilities Change -1.28 % 37.15 % 4.11 % 5.21 % 28.78 %
Seq. Current Assets Change 92.77 % -21.07 % 2.43 % -28.41 % 91.16 %



Working Capital Ratio first quarter 2018 Comment
Stemline Therapeutics Inc's Current Assets grew by 92.77 % in I. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Stemline Therapeutics Inc's Working Capital Ratio to 5.14, Working Capital Ratio remained below Stemline Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 106 other companies have achieved higher Working Capital Ratio than Stemline Therapeutics Inc in first quarter 2018. While total ranking remained unchanged compare to previous quarter at no. .

Explain Working Capital Ratio
Where is STML most successful ?
Working Capital Ratio STML on the trailing twelve month basis
Working Capital Ratio first quarter 2018 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 209
Overall Market # 584


Working Capital Ratio Statistics
High Average Low
31.09 9.6 2.63
(Sep 30 2013)   (Dec 31 2017)




Financial Statements
Stemline Therapeutics Inc's Current Liabilities $ 20 Millions Visit STML's Balance sheet
Stemline Therapeutics Inc's Current Assets $ 101 Millions Visit STML's Balance sheet
Source of STML's Sales Visit STML's Sales by Geography




Companies with similar Working Capital Ratio in the quarter endingMar 31 2018, within Major Pharmaceutical Preparations Industry Working Capital RatioMar 31 2018 MRQ Current AssetsMar 31 2018 MRQ Current Liabilities
Esperion Therapeutics, Inc.  13.79 $ 201.408  Millions$ 14.608  Millions
Dynavax Technologies Corp  13.37 $ 255.396  Millions$ 19.099  Millions
Sarepta Therapeutics, Inc.  13.37 $ 1,219.417  Millions$ 91.196  Millions
Cymabay Therapeutics, Inc.  12.90 $ 231.176  Millions$ 17.918  Millions
Spring Bank Pharmaceuticals, Inc.  12.62 $ 47.768  Millions$ 3.785  Millions
Neurotrope, Inc.  12.55 $ 14.731  Millions$ 1.174  Millions
Viking Therapeutics, Inc.  12.49 $ 78.731  Millions$ 6.302  Millions
Revance Therapeutics, Inc.  12.42 $ 273.418  Millions$ 22.013  Millions
Zafgen, Inc.  12.26 $ 91.422  Millions$ 7.457  Millions
Xbiotech Inc.  12.22 $ 29.749  Millions$ 2.434  Millions
Zogenix, Inc.  12.19 $ 281.327  Millions$ 23.076  Millions
Cytokinetics Inc  11.99 $ 272.339  Millions$ 22.710  Millions
Ovascience, Inc.  11.75 $ 59.133  Millions$ 5.032  Millions
Ovid Therapeutics Inc.  11.52 $ 75.817  Millions$ 6.579  Millions
Oncosec Medical Inc  11.43 $ 32.418  Millions$ 2.835  Millions
Beigene, Ltd.  11.18 $ 1,585.702  Millions$ 141.896  Millions
Flex Pharma, Inc.  11.15 $ 25.640  Millions$ 2.300  Millions
Aldeyra Therapeutics, Inc.  11.07 $ 40.605  Millions$ 3.667  Millions
Aimmune Therapeutics, Inc.  10.86 $ 330.297  Millions$ 30.412  Millions
Agios Pharmaceuticals Inc  10.75 $ 802.993  Millions$ 74.699  Millions
Contrafect Corp  10.62 $ 41.668  Millions$ 3.923  Millions
Epizyme, Inc.  10.43 $ 256.862  Millions$ 24.633  Millions
Paratek Pharmaceuticals, Inc.  10.29 $ 188.228  Millions$ 18.301  Millions
Ardelyx, Inc.  10.28 $ 135.320  Millions$ 13.162  Millions
Aduro Biotech, Inc.  10.19 $ 330.814  Millions$ 32.470  Millions
Aquinox Pharmaceuticals, Inc  10.07 $ 94.223  Millions$ 9.355  Millions
Adamas Pharmaceuticals Inc  9.85 $ 206.090  Millions$ 20.920  Millions
Five Prime Therapeutics Inc  9.79 $ 403.043  Millions$ 41.166  Millions
Xenon Pharmaceuticals Inc.  9.68 $ 36.661  Millions$ 3.788  Millions
Mirati Therapeutics, Inc.  9.56 $ 153.073  Millions$ 16.010  Millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

FCRE's Profile

Stock Price

FCRE's Financials

Business Description

Fundamentals

Charts & Quotes

FCRE's News

Suppliers

FCRE's Competitors

Customers & Markets

Economic Indicators

FCRE's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071